Evidence map›Paper›PMID 35354641›Full record

Observational studyBMJ health & care informatics2022

Machine learning using longitudinal prescription and medical claims for the detection of non-alcoholic steatohepatitis (NASH).

Ozge Yasar, Patrick Long, Brett Harder, Hanna Marshall, Sanjay Bhasin, Suyin Lee, Mark Delegge, Stephanie Roy, Orla Doyle, Nadea Leavitt and 1 more

Abstract readObservational Study
In one paragraph

Observational study in BMJ health & care informatics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Automated Deep Learning Detection of Hepatic Steatosis on Noncontrast Computed Tomography Scans and Discrepancy With Scan Reports.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ozge Yasar *Real World Solutions, IQVIA, London, UK.
Patrick Long *Real World Solutions, IQVIA, Plymouth Meeting, Pennsylvania, USA Patrick.long@iqvia.com.ORCID http://orcid.org/0000-0002-7206-4607
Brett HarderReal World Solutions, IQVIA, Plymouth Meeting, Pennsylvania, USA.
Hanna MarshallReal World Solutions, IQVIA, Plymouth Meeting, Pennsylvania, USA.
Sanjay BhasinReal World Solutions, IQVIA, Plymouth Meeting, Pennsylvania, USA.
Suyin LeeReal World Solutions, IQVIA, Plymouth Meeting, Pennsylvania, USA.
Mark DeleggeTherapeutic Center of Excellence, IQVIA, Durham, North Carolina, USA.
Stephanie RoyReal World Solutions, IQVIA, Plymouth Meeting, Pennsylvania, USA.
Orla DoyleReal World Solutions, IQVIA, London, UK.
Nadea LeavittReal World Solutions, IQVIA, Plymouth Meeting, Pennsylvania, USA.
John RiggReal World Solutions, IQVIA, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo develop and evaluate machine learning models to detect patients with suspected undiagnosed non-alcoholic steatohepatitis (NASH) for diagnostic screening and clinical management.

methodsIn this retrospective observational non-interventional study using administrative medical claims data from 1 463 089 patients, gradient-boosted decision trees were trained to detect patients with likely NASH from an at-risk patient population with a history of obesity, type 2 diabetes mellitus, metabolic disorder or non-alcoholic fatty liver (NAFL). Models were trained to detect likely NASH in all at-risk patients or in the subset without a prior NAFL diagnosis (at-risk non-NAFL patients). Models were trained and validated using retrospective medical claims data and assessed using area under precision recall curves and receiver operating characteristic curves (AUPRCs and AUROCs).

resultsThe 6-month incidences of NASH in claims data were 1 per 1437 at-risk patients and 1 per 2127 at-risk non-NAFL patients . The model trained to detect NASH in all at-risk patients had an AUPRC of 0.0107 (95% CI 0.0104 to 0.0110) and an AUROC of 0.84. At 10% recall, model precision was 4.3%, which is 60× above NASH incidence. The model trained to detect NASH in the non-NAFL cohort had an AUPRC of 0.0030 (95% CI 0.0029 to 0.0031) and an AUROC of 0.78. At 10% recall, model precision was 1%, which is 20× above NASH incidence.

conclusionThe low incidence of NASH in medical claims data corroborates the pattern of NASH underdiagnosis in clinical practice. Claims-based machine learning could facilitate the detection of patients with probable NASH for diagnostic testing and disease management.

Indexed as

Diabetes Mellitus, Type 2Non-alcoholic Fatty Liver DiseaseHumansMachine LearningPrescriptionsRetrospective Studiesartificial intelligenceBMJ Health Informaticsdata sciencemachine learningmedical records

Identifiers

PMID35354641
PMCPMC8968511

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.